Short Interest in Oculis Holding AG (NASDAQ:OCS) Increases By 38.8%

Oculis Holding AG (NASDAQ:OCS) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 34,700 shares, an increase of 38.8% from the February 28th total of 25,000 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily volume of 71,500 shares, the short-interest ratio is presently 0.5 days.

Oculis Trading Down 1.9 %

Shares of NASDAQ OCS traded down $0.37 during mid-day trading on Tuesday, hitting $18.66. The stock had a trading volume of 29,935 shares, compared to its average volume of 46,208. The firm has a market cap of $814.73 million, a P/E ratio of -9.67 and a beta of 0.01. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The business has a 50 day moving average price of $20.50 and a two-hundred day moving average price of $17.62. Oculis has a 1 year low of $10.55 and a 1 year high of $23.08.

Oculis (NASDAQ:OCS) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. On average, equities analysts anticipate that Oculis will post -2.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Oculis

A number of large investors have recently made changes to their positions in OCS. abrdn plc increased its position in Oculis by 23.0% during the 4th quarter. abrdn plc now owns 1,009,424 shares of the company’s stock valued at $17,150,000 after purchasing an additional 188,871 shares during the period. Bank of America Corp DE boosted its stake in shares of Oculis by 58.2% during the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock valued at $493,000 after purchasing an additional 10,667 shares in the last quarter. Citadel Advisors LLC purchased a new position in shares of Oculis during the fourth quarter valued at about $389,000. Bellevue Group AG bought a new position in Oculis in the fourth quarter worth about $170,000. Finally, Geode Capital Management LLC lifted its holdings in Oculis by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock worth $284,000 after buying an additional 1,800 shares during the period. 22.30% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. HC Wainwright cut their price target on Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a report on Thursday, March 13th. Chardan Capital restated a “buy” rating and set a $28.00 price objective on shares of Oculis in a research report on Thursday, March 13th. Finally, Robert W. Baird boosted their target price on Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a research report on Thursday, March 13th.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.